Tandem Diabetes Care, Inc. reported total sales of $234.4 million for the first quarter of 2025, marking a 22% increase compared to $191.7 million in the first quarter of 2024. U.S. sales grew by 15% year-over-year to $150.6 million, driven by over 17,000 pump shipments. Sales outside the United States increased by 35% to $83.8 million, with over 11,000 pump shipments.
The company's gross profit was $118.4 million, resulting in a gross margin of 51%, an improvement from 49% in the same period of 2024. However, Tandem reported a significant operating loss of $120.9 million, compared to a loss of $41.7 million in Q1 2024. This loss included a $75.2 million charge for acquired in-process research and development related to a revised agreement for AMF Medical, along with $9.8 million in impairment and restructuring charges.
The net loss for Q1 2025 was $130.6 million, or $1.97 per share, compared to a net loss of $42.7 million, or $0.65 per share, in Q1 2024. Despite the increased loss, the company reiterated its full year 2025 worldwide sales guidance in the range of $997 million to $1 billion. Tandem also stated its anticipation of returning to positive free cash flow in the second half of 2025 and for the full year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.